Discuss pregnancy plans before starting or changing treatment. Semaglutide, tirzepatide and orforglipron have different advance stopping periods, and the oral contraceptive precautions are not identical across medicines.
Make pregnancy planning part of the prescription
GLP-1 medicines should not be used during pregnancy, and weight loss treatment is not recommended in pregnancy. If treatment is also helping manage diabetes, arrange an alternative glucose-management plan with the care team. Do not stop essential diabetes treatment without a replacement plan.
Tell the prescriber whether pregnancy is possible or planned, even if the plan is several months away. The useful discussion includes contraception, when treatment will stop and who will review other medicines. An online assessment should give you a way to explain circumstances that do not fit a simple yes-or-no field.
Sources: UK Teratology Information Service / BUMPS: GLP-1 receptor agonists in pregnancy; MHRA: GLP-1 medicines for weight loss and diabetes: what you need to know
The advance stopping periods differ
The UK information advises stopping semaglutide at least two months before a planned pregnancy. Tirzepatide should be stopped at least one month beforehand. Foundayo's orforglipron information specifies at least three weeks. These periods are medicine-specific and should be confirmed with your prescriber when making the plan.
Do not use the shortest period from another product or assume that a daily tablet leaves the body immediately. Write down the last planned dose and the clinician's advice about contraception during the interval. If treatment changes before then, ask whether the plan also needs updating.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: UK Summary of Product Characteristics; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
Mounjaro and Foundayo have specific pill precautions
For tirzepatide, people using oral hormonal contraception should use a non-oral method or add barrier contraception for four weeks after starting and after every dose increase. For Foundayo, the corresponding UK advice is 30 days after starting and after each increase. These are different written intervals; follow the information for your actual medicine.
Ask a pharmacist or contraception service to help choose an appropriate approach. Do not stop an existing contraceptive method while waiting for a replacement without advice about protection. Record dose-increase dates, because a new increase starts a new period of additional precautions.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: patient information leaflet; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet
Vomiting and diarrhoea create another issue
Vomiting or severe diarrhoea can affect oral contraceptive reliability separately from a medicine interaction. Follow the leaflet for your contraceptive product and seek prompt advice from a pharmacist or sexual health service if protection may have been reduced. The action depends on the type of pill, timing and circumstances.
If emergency contraception may be needed, say which weight-management medicine and contraceptive you use, and when symptoms and unprotected sex occurred. This is time-sensitive advice; do not wait for the next weight-management review. A general guide cannot safely determine the right option from the medicine name alone.
Sources: MHRA: GLP-1 medicines for weight loss and diabetes: what you need to know
If pregnancy occurs, seek advice promptly
If pregnancy occurs while taking one of these weight-management medicines, stop it and contact the prescriber and maternity or diabetes team promptly. Do not independently stop other essential diabetes medicines. Provide the product, dose and exposure dates. BUMPS explains that limited available data have not established all the risks; an exposure needs individual assessment, not an assumption that harm has occurred.
Breastfeeding requires a separate medicine-specific discussion. Do not assume that a pregnancy stopping interval determines when treatment can be restarted after birth. The clinician needs to consider feeding, glucose management, recovery and the current product information together. Keep the plan coordinated across the teams involved.
Sources: UK Teratology Information Service / BUMPS: GLP-1 receptor agonists in pregnancy; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026; Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: UK Summary of Product Characteristics
Questions, answered.
Is the same advance stopping period used for all four options?
No. Wegovy injection and tablets contain semaglutide and use a two-month interval; tirzepatide uses at least one month; orforglipron uses at least three weeks. Confirm your individual plan.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy FlexTouch: UK Summary of Product Characteristics; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: UK Summary of Product Characteristics; Eli Lilly / electronic medicines compendium: Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
Does a medicine interaction mean all contraception fails?
No. The specific warnings concern oral hormonal contraception. A contraception professional can explain non-oral options and additional precautions suited to you.
Sources: Eli Lilly / electronic medicines compendium: Mounjaro KwikPen: patient information leaflet; Eli Lilly / electronic medicines compendium: Foundayo: patient information leaflet
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- GLP-1 receptor agonists in pregnancyUK Teratology Information Service / BUMPS · Accessed 19 November 2026
- GLP-1 medicines for weight loss and diabetes: what you need to knowMHRA · Accessed 19 November 2026
- Wegovy FlexTouch: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Wegovy tablets: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Mounjaro KwikPen: UK Summary of Product CharacteristicsEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Foundayo: UK Summary of Product Characteristics, revised 3 November 2026Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Mounjaro KwikPen: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
- Foundayo: patient information leafletEli Lilly / electronic medicines compendium · Accessed 19 November 2026
